In particular, the CSF1R inhibitor Pexidartinib approved by the FDA for tenosynovial giant cell tumour (FDA pexidartinib), was rejected by the EMA due to questionable efficacy and observed hepatotoxicity (EPAR Turalio). The gene discussed is CSF1R; the disease is tenosynovial giant cell tumor, diffuse type.